Z inc transporters (ZnT) regulate the passage of zinc across biological membranes out of the cytosol, while Zrt/Irt-like proteins transport zinc into the cytosol 1 . ZnT8, encoded by SLC30A8, is highly expressed in the membrane of insulin granules within pancreatic β cells, where it transports zinc ions for crystallization and storage of insulin 2 . We previously described a loss-offunction (LoF) allele p.Arg138* (rs200185429, c.412C>T) in the SLC30A8 gene that conferred 53% protection against T2D (ref. 3 ). This allele was extremely rare (0.02%) in most European countries, but more common (>0.2%) in Western Finland 3 . We also reported a protective frameshift allele, p.Lys34Serfs*50, conferring 83% protection against T2D in Iceland 3 . Further, the SLC30A8 gene harbors a common variant (rs13266634, c.973C>T) p.Trp325Arg in the carboxy (C)-terminal domain 4 . Whereas the major p.Arg325 allele (>70% of the population) confers increased risk for T2D, the minor p.Trp325 allele is protective 5 .
The mechanisms by which modulation of ZnT8 activity protects against T2D are largely unknown. Several attempts have been made to study loss of Slc30a8 function in rodent models, but the results have been inconclusive; global knockout of Slc30a8 led to either glucose intolerance or had no effect in mice [6] [7] [8] , whereas overexpression improved glucose tolerance without any effect on insulin secretion 9 . A mouse model harboring the equivalent of the human p.Arg138* allele lacked any detectable ZnT8 protein but showed no effect on glucose tolerance 10 . These rodent studies present a complex picture that may not recapitulate the T2D-protective effects of SLC30A8 LoF alleles in humans. We therefore performed detailed metabolic studies in human carriers heterozygous for the LoF allele (p.Arg138*) recruited on the basis of their genotype, performed comprehensive functional studies in human β cell models and compared these with the mouse model carrying the human p.Arg138*-Slc30a8 allele.
A rare loss-of-function allele p.Arg138* in SLC30A8 encoding the zinc transporter 8 (ZnT8), which is enriched in Western Finland, protects against type 2 diabetes (T2D). We recruited relatives of the identified carriers and showed that protection was associated with better insulin secretion due to enhanced glucose responsiveness and proinsulin conversion, particularly when compared with individuals matched for the genotype of a common T2D-risk allele in SLC30A8, p.Arg325. In genomeedited human induced pluripotent stem cell (iPSC)-derived β-like cells, we establish that the p.Arg138* allele results in reduced SLC30A8 expression due to haploinsufficiency. In human β cells, loss of SLC30A8 leads to increased glucose responsiveness and reduced K ATP channel function similar to isolated islets from carriers of the T2D-protective allele p.Trp325. These data position ZnT8 as an appealing target for treatment aimed at maintaining insulin secretion capacity in T2D.
Results
Recruitment by genotype. Given the enrichment of the p.Arg138* SLC30A8 allele in Western Finland, we genotyped >14,000 individuals from the Botnia Study 11 for the SLC30A8 p.Arg138* and the common p.Trp325Arg variants, and identified 71 p.Arg138* SLC30A8 carriers (all heterozygotes; 55 nondiabetic individuals, Fig. 1 ). We then recruited family members of known p.Arg138* carriers to identify additional p.Arg138* carriers and to perform a detailed metabolic study (190 min test meal) in carriers and noncarrier relatives. Of the 79 p.Arg138* carriers (65 new, 14 previously identified) and 103 noncarrier relatives from >21 families (Extended Data Fig. 1 ), 54 and 47, respectively, participated in a test meal, and 31 and 13 participated in an oral glucose tolerance test (OGTT) during a separate second visit ( Fig. 1 and Supplementary Tables 1 and 2). We also had data from previously performed OGTTs within the Botnia Study for 8,436 nondiabetic individuals (55 p.Arg138* carriers; Fig. 1 and Supplementary Tables 2 and 3 ). Of the 136 p.Arg138* allele carriers, none were homozygous for the protective common variant, p.Trp325, and p.Arg138* segregated with p.Arg325 in all families (Extended Data Fig. 1 ). Thus, we present the data in three different ways: (1) p.Arg138* versus all p.Arg138Arg, (2) p.Arg138* versus p.Arg138Arg having at least one p.Arg325 allele (p.Trp325Arg or p.Arg325Arg) and (3) p.Arg325 (p.Trp325Arg or p.Arg325Arg) versus p.Trp325Trp on a background of p.Arg138Arg.
Replicating our previous findings 3 , carriers of p.Arg138* had a reduced risk of T2D (odds ratio (OR) = 0.40, P = 0.003) when analyzing 4,564 T2D (13 p.Arg138* carriers) and 8,183 nondiabetic (55 p.Arg138* carriers) individuals. Additionally, nondiabetic p.Arg138* carriers had lower fasting glucose concentrations than p.Arg138Arg individuals ( Supplementary Tables 4 and 5 ). There were no significant differences in plasma zinc concentrations measured during test meal or OGTT between the groups (data not shown).
Comparison of p.Arg138* versus p.Arg138Arg. The p.Arg138* carriers had lower blood glucose levels during the test meal, especially during the first 40 min (area under curve, P = 0.02), and showed a higher corrected insulin response (CIR) (at 20 min, P = 0.046) than noncarriers (Supplementary Table 6 and Fig. 2a-c) . Similarly, in the larger population-based OGTT cohort, carriers had higher insulin response during OGTT ( Fig. 3a -c, left panel), especially with respect to the early incremental insulin response (P = 0.008) and the insulin/glucose ratio (at 30 min, P = 0.002; Supplementary  Table 4 ). The higher insulin secretory response during OGTT was consistent across different subsets with OGTT data (meta-analysis: CIR, P = 0.002; incremental insulin, P = 2.4 × 10 −4 ; 30 min insulin, P = 3.8 × 10 −4 ) (Supplementary Table 5 ). Of note, the p.Arg138* carriers had significantly lower proinsulin/C-peptide (20 min: P = 0.041; 40 min: P = 0.043) and proinsulin/insulin (20 min: P = 0.006) ratios during the test meal, suggesting effects on proinsulin conversion (Fig. 2d,e ). No differences were seen in glucagon, GLP-1 or free fatty acid (FFA) concentrations during the test meal (Extended Data Fig. 2c-e ). Neither the model-based insulin clearance index nor the ratio of insulin and C-peptide areas under the curve during the test meal differed between p.Arg138* and p.Arg138Arg (Extended Data Fig. 2f,g) .
Comparison of p.Arg138* versus p.Arg138Arg-p.Arg325. The above differences were magnified when we restricted the p.Arg138Arg group to carriers of the common risk variant p.Arg325 (Fig. 2 , middle panels). The early phase (0-40 min) insulin (P = 0.026), insulin/ glucose ratio (P = 0.004) and CIR (P = 0.004; 20 min) were all greater in p.Arg138* carriers versus p.Arg138Arg on a background of p.Arg325 (Supplementary Table 6 ). Both the proinsulin/C-peptide (20 min: P = 0.027, 40 min: P = 0.044) and proinsulin/insulin ratios (20 min: P = 0.003) were reduced in p.Arg138* carriers ( Fig. 2d ,e, middle panels).
Comparison of p.Trp325Trp versus p.
Arg325. The effect of p.Trp325Trp genotype on glucose and insulin response mimicked the effects of p.Arg138* with pronounced early (20 min) insulin (P = 0.032) and C-peptide (P = 0.030) responses during the test meal ( Fig. 2b ,c, right panels, and Extended Data Fig. 2a ), as well as increased insulin secretion (30 min insulin: P = 0.003, 30 min insulin/glucose: P = 0.002, incremental insulin: P = 0.005), lower fasting and 120 min proinsulin (P = 0.006 and P = 0.039, respectively) concentration during OGTT in p.Trp325 carriers ( Supplementary  Table 4 and Fig. 3b ,c, right panels). Moreover, p.Trp325Trp carriers showed a pronounced increased (P = 0.003) early incremental insulin secretion during the intravenous glucose tolerance test (IVGTT) (Extended Data Fig. 3a,b and Supplementary Table 4 ). In patients with newly diagnosed T2D ( Supplementary Table 7 ), the p.Trp325Trp carriers showed a trend (P = 0.12) towards enhanced β cell sensitivity to glucose during the OGTT (Extended Data Fig. 3c ).
Taken together, all human in vivo data on p.Arg138* show enhanced glucose-stimulated insulin secretion combined with enhanced proinsulin conversion as a potential explanation for T2D protection. The common allele p.Trp325 is also associated with protection from T2D and the metabolic effects are similar but more modest than those of p.Arg138*, suggesting that it might also reduce ZnT8 function.
SLC30A8 p.Arg138* and p.Lys34Serfs*50 in human iPSCs. The majority of nonsense SLC30A8 alleles (including p.Arg138* and p.Lys34Serfs*50) that protect against T2D are located in the first four exons of the eight-exon canonical islet SLC30A8 transcript (ENST00000456015) and are predicted to undergo nonsense-mediated decay (NMD), a cell surveillance pathway that reduces errors in gene expression by eliminating messenger RNA transcripts with premature stop codons. To confirm that nonsense SLC30A8 alleles lead to haploinsufficiency through NMD, we used CRISPR-Cas9 to introduce two protective alleles, p.Arg138* and p.Lys34Serfs*50, into the SLC30A8 locus of the SB Ad3.1 human iPSC line (Extended Data Fig. 4a ). Two heterozygous hiPSC lines for the SLC30A8 p.Arg138* allele (clones B1 and A3) and two homozygous hiPSC lines for SLC30A8 p.Lys34Serfs*50 (clones B3 and D3) were generated and compared with an unedited wild type and a CRISPR-Sham hiPSC line. All hiPSC lines passed quality control checks, including karyotyping and pluripotency (Extended Data Fig. 4b ,c).
We subjected our SLC30A8-edited iPSCs to a previously published in vitro endocrine pancreas differentiation protocol 12 (Extended Data Fig. 4 ). At the end of the seven-stage protocol, SLC30A8 expression was significantly reduced in cells heterozygous for the p.Arg138* allele (clone A3 0.06 ± 0.03, P < 0.0001; clone B1 0.04 ± 0.01, P < 0.0001) or homozygous for the p.Lys34Serfs*50 (clone B3 0.04 ± 0.01, P < 0.0001; clone D3 0.04 ± 0.01, P < 0.0001) compared with unedited control cells (1.02 ± 0.13) ( Fig. 4a ). In addition, ZnT8 protein was absent in homozygous p.Lys34Serfs*50 hiPSCderived β-like cells compared with wild-type controls, but was also undetectable in differentiated heterozygous p.Arg138* clones (Fig. 4b,c ), suggesting an impact on differentiation. Indeed, the number of INS-and SLC30A8-transcript expressing cells was reduced in clones with premature stop codons in SLC30A8 (Extended Data Fig. 4d-g) , indicating a reduced formation of β-like cells. To disentangle effects on differentiation from those on expression, allelespecific SLC30A8 expression was quantified by digital droplet PCR 13 in the heterozygous p.Arg138* lines. Of note, p.Arg138* allele-specific SLC30A8 expression was reduced compared to the WT allele (clone A3: 24.3 ± 3.1%, P < 0.0001; clone B1: 22.2 ± 1.7%, P < 0.0001) ( Fig. 4d ). The reduced expression of the mutant SLC30A8 allele (clone A3: 18.2 ± 1.8%; clone B1: 18.6%) compared to the wild-type allele (81.7 ± 1.3%) was confirmed (P < 0.0001) by targeted SLC30A8 mRNA sequencing ( Fig. 4e and Extended Data Fig. 5c ). Although not statistically significant, inhibition of NMD by cycloheximide showed a trend towards greater rescue of the p.Arg138* transcript compared to the p.Arg138Arg transcript (clone A3: 230 ± 61% versus 150 ± 33%, P = 0.28 and clone B1:198 ± 45% versus 152 ± 26%, Fig. 4f ,g). Taken together, these data show that the protective p.Arg138*-SLC30A8 allele undergoes NMD, resulting in haploinsufficiency for SLC30A8. Impact of SLC30A8 loss in a human β-cell line. Since human in vivo studies provided strong evidence for a role for the p.Arg138* on insulin secretion and proinsulin processing, we studied the impact of SLC30A8 loss using short interfering RNA (siRNA)-mediated knockdown (KD) on both phenotypes in a well-characterized human β cell model, EndoC-βH1 (ref. 14 ) . By siRNA, we achieved a 30-65% decrease in SLC30A8 mRNA levels ( Fig. 5a ; P = 0.003, and Extended Data Fig. 7a ; P = 5.93 × 10 −22 ), which resulted in reduced ZnT8 protein levels ( Fig. 5b and Extended Data Fig. 6a ) associated with a reduction in intracellular zinc content (34%, P = 0.002; Fig. 5c ). Assessment of dense core granule zinc content in SLC30A8silenced EndoC-βH1 cells (Extended Data Fig. 6a ), through the use of the cell surface-attached fluorescent zinc probe ZIMIR 15 (Extended Data Fig. 6b ,c) showed a tendency (P = 0.10; Extended Data Fig. 6d ) for reduced Zn 2+ release, which is consistent with the loss of zinc from this compartment and also with previous findings in islets from Slc30a8 null mice 15 . KD of SLC30A8 had no significant effect on stimulated insulin secretion either in response to 20 mM glucose or to the sulfonylurea tolbutamide (which closes K ATP channels; Fig. 5d ). However, basal insulin secretion was significantly increased in siSLC30A8transfected cells (P = 0.048), which reduced marginally the glucose stimulation index (P = 0.26; Fig. 5e ). In addition, the inhibitory effect of diazoxide, a K ATP channel opener, on glucose-stimulated insulin secretion, was significantly reduced (P = 8 × 10 -4 ; Fig. 5d ). There was no effect of SLC30A8 knockdown on insulin content ( Fig. 5f ). We then measured the resting membrane conductance (G m ) in siSLC30A8-transfected cells incubated with 100 µM diazoxide (to activate K ATP channels). In control cells, G m was in agreement with previous reports 16 , while SLC30A8 knockdown reduced G m by 65% (P = 0.002; Fig. 5g ) without altering cell size ( Fig. 5h ).
Indeed, reduced K ATP channel activity is consistent with the reduced expression observed of the genes encoding the K ATP channel subunits, SUR1 (ABCC8) and Kir6.2 (KCNJ11) (P = 0.04 and 0.06 respectively; Fig. 5i ). In addition, insulin secretion elicited by the combination of elevated 50 mM extracellular K + ([K + ] o ) to depolarize the cells and open voltage-gated Ca 2+ channels and 16.7 mM glucose was significantly higher after SLC30A8 knockdown (P = 0.002; Fig. 5j ). The proinsulin-insulin ratios (both total content; P = 0.007 and secreted hormones; P = 0.004) and proinsulin concentrations (total content; P = 0.011, secreted in media; P = 0.017) were decreased in siSLC30A8-transfected cells, but no differences in either protein or mRNA levels of genes (PCSK1, CPE and PCSK2) involved in proinsulin processing in SLC30A8 KD cells was observed ( Fig. 5m -q and Extended Fig. 7a ). However, we did observe increased AKT phosphorylation (pAKT-473) and improved cell survival under ER stress (P = 0.016 and 0.032, respectively; Fig. 5r -t) in SLC30A8 KD cells. We next examined the effects of SLC30A8 knockdown on gene expression in EndoC-βH1 cells by mRNA sequencing (RNA-seq) of siSLC30A8 treated and siScramble cells (n = 8 for both, see Supplementary Note). We observed a total of 674 significantly differently expressed genes among 12,956 protein-coding genes that passed the quality control filters (Extended Data Fig. 7 and Supplementary Dataset 1). RNA-seq confirmed the reduction in KCNJ11 and ABCC8 expression in SLC30A8 KD cells (P = 2.6 × 10 −18 and P = 2.04 × 10 −9 , respectively; Extended Data Fig. 7c ) as seen earlier by quantitative PCR (qPCR) (Fig. 5i ). In addition, further genes involved in the regulation of β cell excitability/exocytosis, including CACNA1C, were upregulated in KD cells (Extended Data Fig. 7c ). Moreover, expression of genes associated with β cell maturation and development were also influenced by SLC30A8 knockdown, with decreased expression of NKX6.1 and PDX1 and increased expression of SOX4, SOX6 and SOX11 (Extended Data Fig. 7b ). A pathway-enrichment analysis of differentially expressed genes showed enrichment of genes involved in the WNT signaling and insulin secretion pathways (Extended Data Fig. 7 and Supplementary Dataset 1). A global gene-set enrichment analysis of all expressed genes (N = 12,956) using a gene ontology database showed enrichment of genes involved in positive regulation of TOR signaling (Extended Data Fig. 7 ) in knockdown cells. Collectively, these data demonstrate a link between SLC30A8 expression and transcriptional networks involved in cell development, cell fate and plasma membrane polarization. Metabolic phenotype of Slc30a8 p.Arg138* mice. Since neither global nor tissue-specific Slc30a8 knockout mouse models have recapitulated the human phenotype in carriers of the SLC30A8 p.Arg138* allele, we attempted to overcome this problem by using a mouse model carrying the human Slc30a8 p.Arg138* allele 10 . On a standard chow diet there was no evidence of enhanced insulin . d-f, Effect of KD on insulin secretion (normalized to total insulin content and average siScramble basal secretion) stimulated by glucose and K ATP channel regulators (as labeled, and n = 12) (d), glucose stimulation index induced by 20 mmol l −1 glucose stimulation (n = 12) (e) and insulin content (n = 48) (f). g-j, Effect of siSLC30A8 KD on K ATP channel conductance (G m , siScramble n = 10 cells, siSLC30A8 n = 9 cells) (g), cell size (n = 5) (h), expression of K ATP channel subunits (n = 5) (i) and on insulin secretion stimulated by KCl and high glucose (n = 10) (j). k,l, Effect of KD on proinsulin processing estimated by proinsulin/insulin ratio (n = 7) (k) and proinsulin concentration (n = 7) (l). m-q, Effect of KD on protein expression of proinsulin processing enzymes PC1/3, CPE (immunoblot (m) and densitometry (n, n = 5; o, n = 4)) and PC2 (densitometry (p) (n = 4) and immunoblot (q)). r-t, Effect of KD on basal (5.5 mM glucose) AKT phosphorylation (densitometry (r) (n = 5) and immunoblot (s); phospho-AKT-Ser473, total AKT) and cell viability under ER stress (t, MTT assay, n = 5). Black bar graphs: control cells (siScramble); red bar graphs: SLC30A8 knockdown cells (siSLC30A8). Blots have been cropped and the corresponding full blots are available in the Source Data files. Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 using Mann-Whitney U-test; # P < 0.05; ### P < 0.01 using one-sample t-test; Bonferroni multiple correction for four conditions (d). secretion 10 but when subjected to a high-fat diet (HFD) the mice showed a significant increase in insulin secretion (P = 0.0016; Fig. 6i ), and similar changes in proinsulin/insulin (P = 0.0004) and proinsulin/C-peptide ratios (P = 0.0001) as seen in human carriers ( Fig. 6f,g) . No significant changes were seen in insulin clearance, glucose or insulin tolerance ( Fig. 6h ,j,k).
Impact of p.Arg138* on cytosolic zinc in INS-1 cells.
Although we found no evidence for the presence of a truncated protein in the human p.Arg138* β cell model ( Fig. 4) , as also reported for the p.Arg138* mice 10 , we still explored the possibility that a truncated protein could result from mRNA evading NMD. Transient overexpression of tagged ZnT8 p.Arg138* fusion protein in a rat insulinoma cell line, INS-1E, showed distinct punctate distribution patterns, consistent with localization of the truncated ZnT8 protein to secretory granules, as previously observed with the full-length protein 17 (Extended Data Fig. 8a-c) . Additionally, western blotting showed stable expression of truncated ZnT8 in native INS-1E cells (Extended Data Fig. 8d ).
To investigate the effects of a truncated ZnT8 protein on cytosolic free Zn 2+ , we used a genetically encoded Zn 2+ sensor, eCALWY-4 (ref. 18 ). Overexpression of the truncated protein (p.Arg138*; Extended Data Fig. 8e ,f) had no impact on cytosolic free Zn 2+ when expressed in INS-1 (832/13) cells (Extended Data Fig. 8g ).
Influence of SLC30A8 p.Trp325Arg in primary human islets.
Although we were unable to study the effects of the rare T2Dprotective alleles in primary human islets, we were able to assess the impact of the p.Trp325Arg genotype on in vitro insulin and glucagon secretion. Islets obtained from cadaveric p.Trp325 carriers secreted more insulin (P = 0.0153) than p.Arg325Arg carriers when stimulated with high glucose (16.7 mM) and depolarizing [K + ] o (70 mM), in line with findings for SLC30A8 knockdown in EndoC-βH1 ( Fig. 7a,b ). Interestingly, a trend towards increased glucose responsiveness was already observed at submaximal glucose stimulation (6 mM) ( Fig. 7c ). Increasing glucose from 1 mM to 6 mM stimulated insulin secretion 2.2-(P = 0.031) and 2.7 (P = 0.012)-fold in p.Arg325 and p.Trp325 carriers, respectively, with no effect on insulin content ( Fig. 7c,d ).
As SLC30A8 is highly expressed in human alpha cells 1 , we also measured glucagon secretion from the same islets ( Fig. 7e ,f). In islets from p.Arg325Arg donors, 6 mM glucose inhibited glucagon secretion by ~50% compared to 1 mM glucose. In islets from p.Trp325Arg donors, glucagon secretion at 1 mM glucose was reduced by 50% (P = 0.033) compared to p.Arg325Arg donors, with no effect on glucagon content (Fig. 7e,f ).
Finally we explored coexpression of SLC30A8 with relevant candidate genes (INS, GCG, encoding proinsulin processing and K ATP channel subunits) as well as the impact of p.Trp325Arg on their expression ( Fig. 7g-j) . SLC30A8 transcript levels showed strong positive correlation with expression of all candidate genes (GCG, P ≤ 1.3 × 10 −7 , PCSK1, P ≤ 1.5 × 10 −7 , PCSK2, P ≤ 4.6 × 10 −10 , CPE, P ≤ 3.2 × 10 −6 , KCNJ11, P ≤ 7.1 × 10 −7 and ABCC8, P ≤ 1.6 × 10 −11 ) except INS. The protective p.Trp325 allele showed a trend (nonsignificant) of decreased SLC30A8 expression (P = 0.053), as well as genes involved in proinsulin processing such as PCSK1 (P = 0.041), PCSK2 (P = 0.045) and ABCC8 (P = 0.049).
Taken together, these data suggest that the common T2Dprotective allele (p.Trp325) may also improve the response to a glucose challenge (Figs. 2 and 3) by enhancing insulin secretion and possibly by reducing glucagon secretion in primary human islets.
Discussion
The current study demonstrates the strengths of using human models for studying the consequences of variants associated with human diseases. Although over 30 T2D-protective LoF or missense alleles in SLC30A8 have been reported 19 , previous studies in rodents 6, 17, [20] [21] [22] have failed to provide a mechanistic explanation for this protection. This human study robustly shows that enhanced insulin responsiveness to glucose, combined with enhanced proinsulin processing, contributes to the protection from T2D. As all LoF carriers had the common risk p.Arg325 allele on the same haplotype, the effect of the LoF allele was most evident when compared against p.Arg325 carriers, emphasizing the importance of considering the genetic background of human LoF carriers.
In our human iPSC-derived β-like cells, two different LoF alleles (p.Arg138* and p.Lys34Serfs*50) show a clear reduction in SLC30A8 expression, suggesting that NMD-induced haploinsufficiency is likely a common mechanism for rare LoF alleles in SLC30A8. Although a recent study showed increased zinc transporter activity for the common risk variant p.Arg325 (ref. 23 ), it should be kept in mind that the common p.Trp325Arg locus is complex, as another 3′ untranslated region variant (rs3802177) is in strong linkage disequilibrium with p.Trp325Arg. This variant (rs3802177) may potentially affect SLC30A8 transcription/translation, further modulating the effect of p.Trp325Arg on ZnT8 function.
Interestingly, in our human iPSC-based model of SLC30A8 LoF mutations (p.Arg138* and p.Lys34Serfs*50), loss of ZnT8 protein decreased the formation of INS + cells. In support of this, we observed decreased expression of multiple genes associated with β cell development (including PDX1) and changes in expression of genes involved in WNT signaling (including TCF7L2) after partial ZnT8 loss (knockdown) in the human EndoC-βH1 cell line. However, insulin content was not affected, suggesting that partial ZnT8 loss is unlikely to affect β cell development. In support of this, complete ZnT8 null mice were viable, with preserved β cell function 6, 9, 10 . We have not been able to examine this in humans, as we did not find any human homozygous for SLC30A8 LoF alleles.
Whereas data from all our substudies are consistent with increased insulin secretion, the precise molecular mechanisms for the involvement of zinc and zinc transporters remain elusive.
Data derived from the human β cell line show a clear decrease in intracellular zinc content and a trend towards a reduction in cosecreted granular zinc after ZnT8 loss. These observations are consistent with previous rodent studies demonstrating that loss of ZnT8 function reduces total islet zinc content (including R138* mice 10 ) as well as free Zn 2+ in the cytosol and granules 6, 9, 17, 24 . The LoF p.Arg138* and p.Lys34Serfs*50 alleles in humans are likely to exert similar effects on intracellular and granular zinc concentrations. In the present study, overexpression of the truncated p.Arg138* protein in INS-1 cells did not result in changes in cytosolic zinc concentrations, which is consistent with haploinsufficiency. In contrast, a recent human study showed that the T2D-risk p.Arg325 allele was associated with higher islet zinc concentrations 25 . In support of a potential role for zinc in the development of diabetes, Zn 2+ plays an important role as a regulator of cellular excitability 26 in the central nervous system. In β cells, Zn 2+ -induced inhibition of L-type voltage-gated Ca 2+ channels could result in inhibition of insulin secretion 27 , whereas, Zn 2+ has been reported to directly activate K ATP channel currents 28 . The downregulation of the K ATP channel subunit genes following SLC30A8 knockdown suggests that there is coordinated expression of these genes. It is therefore tempting to hypothesize that SLC30A8 expression may contribute to the normal K ATP channel density in both β and α cells, but this remains to be demonstrated. The combined consequence of a reduction in K ATP channel gene expression and a reduction in para/ autocrine electrophysiological regulation (on calcium and K ATP channel activities) by Zn 2+ could contribute to enhanced insulin secretion, as well as reducing glucagon secretion at low glucose levels. Indeed, a similar effect on the secretory capacity of alpha cells has been observed on inhibition of K ATP channel activity using tolbutamide 29 . Zn 2+ is essential for proper insulin crystallization, and loss of ZnT8 results in reduced dense core granules and increased granule diameter possibly due to more noncrystalline insulin, which is expected to be released rapidly during exocytosis 6, 17, 30 . The increased basal insulin secretion seen in the human β cell line following SLC30A8 knockdown and also reported in islets from Slc30a8 null mice 17 , who also display impaired insulin crystallization, suggest that there is preferential release of noncrystalline insulin. It has also been suggested that increased insulin clearance could explain the decrease in circulating insulin concentrations 20 . However, we did not find any support for changes in insulin clearance in human p.Arg138* carriers or p.Arg138* mice on HFD, nor did we see any effect on the incretin hormone GLP-1 in humans. In contrast to the consistent effect of human p.Arg138* and p.Trp325Arg on proinsulin processing, studies in mice following the loss of ZnT8 have reported inconsistent effects on proinsulin processing, ranging from inhibitory effects 20, 21 to beneficial effects in transgenic Trp325Arg mice on HFD 22 . The reasons for this remain unclear, but since blocking the insulin receptor prevents the positive effect on insulin processing in p.Arg138* mice 10 , it is possible that insulin receptor signaling modulates the effect of loss of ZnT8 on proinsulin processing.
The most reproducible finding in all the substudies of SLC30A8 loss was enhanced glucose-stimulated insulin secretion associated with increased conversion of proinsulin to C-peptide and insulin. Carriers of the p.Trp325 T2D-protective allele also showed a similar phenotype, consistent with previous published studies reporting impaired proinsulin conversion in carriers of the risk p.Arg325 allele 31, 32 . It has been suggested that it takes some time for insulin to mature and become biologically active 33, 34 . It is therefore possible that the pronounced effect of the LoF T2D-protective allele at 20 and 40 min of the test meal could reflect an effect on the time course of insulin maturation.
Our study has both strengths and limitations. Among its strengths are the comprehensive studies in humans recalled by their genotype in a region of the world where the p.Arg138* allele is enriched. The complementary studies in both human cell lines, as well as the humanized mice, can also be considered as a strength. A limitation is the inconclusive measurement of zinc in different cellular compartments and characterization of the insulin granule cargo. This will require the development of better intracellular sensors for zinc, which will enable such studies in the future.
In conclusion, our data consistently demonstrate that heterozygosity for a LoF allele p.Arg138* and homozygosity for a common allele p.Trp325Trp of SLC30A8 are associated with increased insulin secretion capacity and a lower risk of developing T2D and in the absence of any on-target adverse events. Therefore, ZnT8 remains an appealing safe target for antidiabetic therapies aimed at preserving β cell function.
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Methods
Human study population. The Botnia Study has been recruiting patients with T2D and their family members in the area of five primary health care centers in Western Finland since 1990. Individuals without diabetes at baseline (relatives or spouses of patients with T2D) have been invited for follow-up examinations every 3-5 years (ref. 11 ). The Prevalence, Prediction and Prevention of diabetes (PPP)-Botnia Study is a population-based study in the same region, including a random sample of 5,208 individuals aged 18 to 75 years from the population registry 38 . Diabetes Registry Vaasa (DIREVA) is a regional diabetes registry of >5,000 diabetic patients from Western Finland (Botnia region) 39 . In the current study, we included >14,000 individuals (Botnia family study = 5,678, PPP = 4,862 and DIREVA = 3,835). All participants gave their written informed consent and the study protocol was approved by the Ethics Committee of Helsinki University Hospital, Finland (the Botnia studies) and the Ethics Committee of Turku University Hospital (DIREVA). Study participants and their clinical measurements in the Verona Newly Diagnosed Diabetes Study (VNDS; Extended Data Fig. 3c ) are described in the Supplementary Note.
OGTT, test meal and IVGTT. Subjects maintained a weight-maintaining diet and avoided vigorous exercise for 3 d before the OGTT (Fig. 3 ) or test meal ( Fig. 2 and Extended Data Fig. 2) , which were performed after an overnight fast. Height, weight, hip and waist circumferences, fat percentage (%, bioimpedance analyzer) and blood pressure (sitting, three measurements after 5 min rest) were measured. The participants ingested 75 g dextrose (in a couple of minutes, OGTT) or a 526-kcal mixed meal (in 10 min, test meal: 76 g carbohydrate, 17 g protein and 15 g fat). Blood samples were drawn from an antecubital vein for plasma (P-) glucose and serum (S-) insulin and C-peptide at 0, 30, 120 min during the OGTT; for P-glucose, P-glucagon, S-insulin, S-C-peptide, S-zinc and total S-GLP-1 at 0, 20, 40, 70, 100, 130, 160 and 190 min during the test meal. Test-meal samples for S-FFA were collected at 0, 40 and 120 min and for S-proinsulin at 0, 20, 40 and 130 min, respectively. Urine was collected between 0 and 70 and between 70 and 190 min for the determination of glucose and zinc excretion during the test meal. Details about IVGTT (Extended Data Fig. 3 ) are provided in the Supplementary Note. Supplementary Note for details (Figs. 2 and 3 and Extended Data Fig. 3a,b) . CIR was calculated for test meal (at 20 min) and OGTT (at 30 min) using the formula CIR(t) = Ins(t) × 100/ [Gluc(t) × (Gluc(t) − 3.89)], where Ins(t) and Gluc(t) are insulin (mU l −1 ) and glucose concentrations (mmol l −1 ) at the sample time point (min) 40 . Estimation of the insulin clearance index was done on the model-based estimation of glucose-, insulin-and C-peptide curves during the test meal, using the equation AUC ISR / [AUC ins + (I basal − I final ) × MRT ins ], where AUC ISR is the area under the curve of insulin secretion rate, AUC ins is the area under the curve of insulin concentration, I final is insulin concentration at the end and I basal is insulin concentration at the beginning of the study 41 . MRT ins is the mean residence time of insulin, and was assumed to be 27 min, as reported previously 42 .
Biochemical measurements. See the
Genetic association analysis. The genotype data were obtained as described in the Supplementary Note. All the quantitative traits were inversely normally transformed before the analyses. The family-based recall study included only nondiabetic subjects during the test meal. Association analysis of rare p.Arg138* with glycemic indices obtained during the family-based recall test meal study (Fig. 2 (left and middle panels), Extended Data Fig. 2 and Supplementary Table 6 ) was performed using family-based association analyses (orthogonal model together with 100,000 Monte Carlo permutations) adjusting for age, sex, body mass index (BMI) and, additionally, other covariates (genotype of p.Trp325Arg for middle panel only) as implemented in QTDT (v.2.6.1, https://csg.sph.umich.edu/abecasis/QTDT/) 35 . Association analysis of common p.Trp325Arg with glycemic indices obtained during the family-based recall test meal study (Fig. 2 (right panels) , Extended Data Fig. 2 and Supplementary Table 6 ) was performed using QFAM family-based association test with 100,000 permutations to correct for any family structure as implemented in PLINK 36 (--qfam-total, --mperm 100,000, http://zzz.bwh. harvard.edu/plink/contact.shtml#cite). The association analysis of p.Arg138* and p.Trp325Arg with glycemic traits during OGTT studies including only nondiabetic individuals ( Fig. 2 and Supplementary Tables 4 and 5 ) and IVGTT (Extended Data Fig. 3 ) was performed using mixed linear model considering genetic relatedness among samples as implemented in GCTA (v.1.91, http://cnsgenomics.com/software/ gcta) 37 . The fixed-effects meta-analysis of all OGTT studies (Supplementary Table 5 ) was performed using the METAL software package (http://www.sph.umich.edu/ csg/abecasis/metal/) 43 . The linear mixed model (adjusting for genetic relatedness) was also used for T2D association analysis.
iPSC generation, differentiation and genome editing. iPSC generation and maintenance. The hiPSC SB Ad3.1 was previously generated and obtained through the IMI/EU-sponsored StemBANCC consortium via the Human Biomaterials Resource Centre, University of Birmingham (http://www.birmingham.ac.uk/ facilities/hbrc) ( Fig. 4 and Extended Data Figs. 4 and 5) . Human skin fibroblasts were obtained from a commercial source (Lonza CC-2511, tissue acquisition number 23447). They had been collected from a Caucasian donor with no reported diabetes with fully informed consent and with ethical approval from the National Research Ethics Service South Central Hampshire research ethics committee (REC 13/SC/0179). The fibroblasts were reprogrammed to pluripotency as previously described 44 and were subjected to the following quality control checks: SNP-array testing via Human CytoSNP-12 v.2.1 beadchip (Illumina, catalog no. WG-320-2101), DAPI-stained metaphase counting and mFISH, flow cytometry for pluripotency markers (BD Biosciences, catalog nos. 560589 and 560126) and mycoplasma testing (Lonza, catalog no. LT07-118).
CRISPR-Cas9-mediated generation of p.Arg138* and p.Lys34Serfs*50 hiPSC line.
Several guide RNAs (gRNAs) were designed using the MIT CRISPR tool (http:// crispr.mit.edu/) to target near exon 2 and exon 3 of SLC30A8 (ENST00000456015). The gRNAs were also subjected to an additional BlastN search (www.ensembl.org) to confirm specificity and no additional off-target sites were identified. To generate SLC30A8 p.Arg138*, the target site for CRISPR-Cas9 mutagenesis (Supplementary Table 8 ) was subcloned into the BsbI restriction sites within the gRNA structure in the pX330 (ref. 45 ) plasmid that was previously modified to contain a puromycin selection cassette. A single-strand oligonucleotide repair template for homology-directed repair (HDR) was synthesized by Eurogentec, stabilized by addition of a phosphorothioate linkage at the 5′ end, and contained two nucleotide changes: (1) the T2D-protective nonsense mutation at codon-138 (c.412C>T, p.Arg138*), which also mutated the protospacer adjacent motif sequence and (2) a silent mutation at codon-139 (c.417 A>T, p.Ala139Ala) to introduce an AluI restriction site for genotyping. Human iPSCs were cotransfected with the SLC30A8-px330-puromycin resistant vectors and the HDR repair template using Fugene6 according to the manufacturer's guidelines (Promega, catalog no. E2691). Following transient puromycin selection, single clones were picked and expanded as described previously 46 . Genotyping PCR was performed using primers (primer pair 1, Supplementary Table 8 ) to amplify the targeted region followed by AluI restriction digest. Successfully targeted clones were confirmed via Sanger sequence and monoallelic sequencing was performed by TA-cloning (pGEM-T Easy Vector System; Promega, catalog no. A1360) of the PCR amplicons. From 96 clones, 11 clones were heterozygous for p.Arg138*, four of which contained indels in the nontargeted allele. The CRISPR-Sham hiPSC control line (p.Arg138Arg) was generated from hiPSC cells that went through the CRISPR pipeline without being edited at the SLC30A8 locus. The two p.Arg138* clones (A3 and B1) and the unedited control line (p.Arg138Arg) passed quality control checks that included repeat chromosome counting and pluripotency testing. Both p.Arg138* clones were heterozygous for the c.412C>T, p.Arg138*, while the silent variant at codon-139 (c.417A>T, p.Ala139Ala) was present in both alleles. Description of p.Lys34Serfs*50 hiPSC line generation is provided in the Supplementary Note.
In vitro differentiation of hiPSCs towards β-like cells. Directed differentiation of hiPSCs towards β-like cells was performed using a previously published protocol 12, 47 . hiPSCs were seeded on Growth Factor Reduced Matrigel-coated CellBind 12-well tissue culture plates (Corning, catalog nos 356230 and 3336) at a cell density of 1.3 × 10 6 in mTesR1 (Stem Cell Technologies, catalog no. 05850) with 10 μM Y-27632 dihydrochloride (Abcam, catalog no. ab120129). The following morning, hiPSCs were fed mTesR1 media for >4 h before starting the seven-stage differentiation protocol described in the Supplementary Note.
Quantification of SLC30A8 gene expression in β-like cells derived from CRISPRedited hiPSCs. Expression of SLC30A8 was measured at the end of stage 7 using qPCR. Briefly, RNA was extracted using TRIzol Reagent (Life Technologies, catalog no. 15596026) according to the manufacturer's instructions. Complementary DNA was amplified using the GoScript Reverse Transcription Kit (Promega, catalog no. A5000). qPCR was performed using 40 ng of cDNA, TaqMan Gene Expression Master Mix (Applied Biosystems, catalog no. 4369017) and primer/probes for SLC30A8 (Hs00545182_m1) or the housekeeping gene TBP (Hs00427620_m1). Gene expression was determined using the ΔΔCT method by first normalizing to TBP and then to the control p.Arg138Arg (n = 7-13 wells from three differentiations).
Allele-specific SLC30A8 expression in β-like cells derived from CRISPR-edited hiPSCs. Stage 7 cells were treated with 100 μg ml −1 cycloheximide (Sigma, catalog no. C4859) or DMSO (Sigma, catalog no. D2650) for 4 h at 37 °C (ref. 48 ) before RNA and cDNA synthesis as above. Allele-specific expression was measured using the QX10 Droplet Digital PCR System and C1000 Touch Thermal Cycler according to manufacturer's guidelines (Bio-Rad). Custom primers (primer pair 2, Supplementary Table 8 ) and probes for the detection of p.Arg138* variant were designed using Primer3Plus (Applied Biosystems): FAM probe (R138; CT, Supplementary Table 8 )), VIC probe (X138; TT, Supplementary Table 8 ). The specificity of the probes was confirmed by droplet digital PCR using R138 or X138 templates (Extended Data Fig. 5 ). Results were analyzed using Quanta Soft software (Bio-Rad) and presented as a ratio of wild-type to HDR-edited allele expression (n > 4 wells from two differentiations).
Western blot of ZnT8. We used highly specific antibody for ZnT8 as developed by Merriman et al. 49 (Supplementary Note). The signal detected corresponded to a protein of 30-34 KDa consistent with the previous publication 49 .
Gene expression measurements in β-like cells derived from CRISPR-edited hiPSCs. Allele-specific SLC30A8 expression by targeted RNA sequencing ( Fig. 4e and Extended Data Fig. 5c ) and other transcript expression in hiPSC-derived β-like cells by RNAscope (Extended Data Fig. 4e-g) are detailed in the Supplementary Note.
EndoC-βH1 culture. The results obtained in EndoC-βH1 are from two distinct teams (Helsinki and Oxford) with different batches of EndoC-βH1 cultures (Fig. 5 ). Here, we report both methods and specify for each experiment the origin of the culture (Helsinki or Oxford). EndoC-βH1 cells were cultured in medium and grown on a matrix as described previously 50 and tested negative for mycoplasma.
SLC30A8 knockdown in EndoC-βH1 cells. In Oxford, EndoC-βH1 cells were transfected with 10 nM siRNA (either SMARTpool ON-TARGETplus SLC30A8 or scramble (Dharmacon, catalog no. L-007529-01)) and Lipofectamine RNAiMAX (Life Technologies, catalog no. 13778-075) according to the manufacturer's instructions for a total of 72 h. In Helsinki, EndoC-βH1 cells were transfected using Lipofectamine RNAiMAX (Life Technologies). 20 nM siRNA ON-TARGETplus siRNA SMARTpool for human SLC30A8 gene (Dharmacon, catalog no. L-007529-01) and ON-TARGETplus Non-targeting pool (siNT or Scramble) (Dharmacon, catalog no. D-001810-10-05) were used following the protocol described previously 51 . Cells were collected 96 h post-transfection for further studies.
Insulin secretion measurements in EndoC-βH1 cells. In Oxford, cells were subjected to static insulin secretion assays 72 h after siRNA transfection as described previously 51 , apart from the following modifications: cells were stimulated for 1 h with 1 mM glucose, 20 mM glucose, 1 mM glucose + 200 μM tolbutamide or 20 mM glucose + 500 μM diazoxide. Insulin levels were measured in both supernatants and cells using the Insulin (human) AlphaLISA Detection Kit and EnSpire Alpha Plate Reader (PerkinElmer, catalog nos AL204C and 2390-0000, respectively). Cell count per well was measured via CyQUANT Direct Cell Proliferation Assay (ThermoFisher, catalog no. C35011). Data are presented as insulin secretion normalized to percentage of insulin content from the control condition. RNA extraction, cDNA synthesis and quantitative PCR with reverse transcription (qRT-PCR) were performed as above (section on 'Quantification of SLC30A8 gene expression in β-like cells derived from CRISPR-edited hiPSCs') to determine SLC30A8 knockdown and expression of the K ATP channel genes (ABCC8 Hs01093752_m1 and KCNJ11 Hs00265026_s1; ThermoFisher Scientific). In Helsinki, EndoC-βH1 cells were transfected with 20 nM siRNA and Scramble control 52 . Following 96 h of siRNA transfection, cells were incubated overnight in 1 mM glucose containing EndoC-βH1 culture medium. At 1 h before the glucose stimulation assay, the media was replaced by βKREBS (Univercell Biosolution) without glucose. Cells were stimulated with 16.7 mM glucose and 50 mM KCl (Sigma-Aldrich) in βKREBS for 30 min at 37°C in a CO 2 incubator. The cells were then washed and lysed with TETG (Tris pH 8, Triton X-100, glycerol, NaCl and EGTA) solution (Univercell Biosolution) for measurement of total insulin content. Secreted and intracellular insulin were measured using a commercial human insulin ELISA kit (Mercodia) as per manufacturer's instructions (Helsinki).
Electrophysiological measurements in EndoC-βH1 cells (Oxford). SLC30A8 was knocked down in EndoC-βH1 as above. K + ATP channel conductance was measured in a perforated patch whole-cell configuration, and patch-clamped using an EPC 10 amplifier and HEKA pulse software. KREBS extracellular solution was perfused in at 32 °C and contained: 138 mM NaCl, 3.6 mM KCl, 0.5 mM MgSO 4 , 10 mM HEPES, 0.5 mM NaH 2 PO 4 , 5 mM NaHCO 3 , 1.5 mM CaCl 2 , 1 mM glucose and 100 μM diazoxide (Sigma-Aldrich, catalog no. D9035). The perforation of the membrane was achieved using an intrapipette solution containing: 0.24 mg ml −1 amphotericin B, 128 mM K-gluconate (Sigma, catalog nos Y0000005 and G4500, respectively), 10 mM KCl, 10 mM NaCl, 1 mM MgCl 2 , 10 mM HEPES, pH 7.35 (KOH). Conductance data are normalized to cell size and presented as pS pF −1 . Expression of ABCC8, KCNJ11, B2M and TBP were measured via qPCR as above (section on 'Quantification of SLC30A8 gene expression in β-like cells derived from CRISPR-edited hiPSCs').
Other assays in EndoC-βH1 cells. Other assays, including insulin and proinsulin secretion and content, immunoblotting (ZnT8, CPE, PC2, phospho-AKT-Ser473 and AKT), cell viability assay (MTT), Zinpyr-1-based zinc staining, monitoring of stimulated zinc secretion using ZIMIR in EndoC-βH1 cells and RNA (mRNAs) sequencing of EndoC-βH1 cells, are described in the Supplementary Note.
Data analyses. Data are reported as mean (s.e.m.). Statistical analyses were performed using Prism 6.0 (GraphPad Software). All parameters were analyzed using Mann-Whitney U-test or one-sample t-test as indicated (two-tailed; Fig. 5 ). See the Supplementary Note for a description of RNA sequencing analysis.
Mouse model. Animals. All procedures were conducted in compliance with protocols approved by the Regeneron Pharmaceuticals Institutional Animal Care and Use Committee. The Slc30a8 p.Arg138* mouse line (Fig. 6) is made in pure C57BL/6 background by changing nucleotide 409 from T into C in exon 3, which changes the arginine into a stop codon 10 . The mutated allele has a self-deleting neomycin selection cassette flanked by loxP sites inserted at intron 3, deleting 29 base pairs (bp) of endogenous intron 3 sequence. Mice were housed (up to five mice per cage) in a controlled environment (12-h light/dark cycle, 22 °C, 60-70% humidity) and fed ad libitum with either chow (Purina Laboratory 23 Rodent Diet 5001, LabDiet) or HFD (Research Diets, D12492; 60% fat by calories) starting at age 20 weeks. All data shown are compared to their respective wild-type littermates.
Glucose tolerance test. Mice were fasted overnight (16 h) followed by oral gavage of glucose (Sigma) at 2 g kg −1 body weight. Blood samples were obtained from the tail vein at the indicated times and glucose levels were measured using the AlphaTrak2 glucometer (Abbott). Submandibular bleeds for insulin were done at 0, 15 and 30 min postinjection in a separate experiment so as not to interfere with glucose levels.
Hormone measurements. Submandibular bleeds of overnight fasted (16 h) animals were done in the morning. Plasma insulin or proinsulin were analyzed with the mouse insulin/proinsulin ELISA (Mercodia), and C-peptide was analyzed with the mouse C-peptide ELISA (ALPCO). All ELISAs were performed according to the manufacturer's instructions.
Data analyses for mouse studies. Data are reported as mean (s.e.m.). Statistical analyses were performed using Prism 8.0 (GraphPad Software). All parameters were analyzed by two-way analysis of variance (ANOVA) (repeated measurements) combined with Sidak's multiple comparison test or Mann-Whitney U-test (two-tailed), as indicated ( Fig. 6 ).
Expression of p.Arg138* alteration in INS-1E.
Details are provided in the Supplementary Note (Extended Data Fig. 8 ).
Human pancreatic islets. Experiments on primary human pancreatic islets ( Fig. 7) were independently performed in two places: Oxford and Lund University Diabetes Center (LUDC).
Human pancreatic islets from Oxford. Human pancreatic islets were isolated from deceased donors under ethical approval obtained from the human research ethics committees in Oxford (REC: 09/H0605/2, NRES committee South Central-Oxford B). All donors had given informed research consent as part of the national organ donation program. Islets were obtained from the Diabetes Research & Wellness Foundation Human Islet Isolation Facility, OCDEM, University of Oxford. All methods and protocols using human pancreatic islets were performed in accordance with the relevant guidelines and regulations in the UK (Human Tissue Authority). For in vitro insulin secretion, islets were pre-incubated in Krebs-Ringer buffer (KRB) containing 2 mg ml −1 BSA and 1 mM glucose for 1 h at 37 °C, followed by 1-h stimulation in KRB supplemented with 6 mM glucose. Insulin content of the supernatant was determined by radioimmunoassay (Millipore UK) as described previously 53 .
Human pancreatic islets from LUDC. Human pancreatic islets were obtained from the Human Tissue Laboratory (Lund University, www.exodiab.se/home) in collaboration with The Nordic Network for Clinical Islet Transplantation Program (www.nordicislets.org) 54, 55 . All the islet donors provided their consent for donation of organs for medical research and the procedures were approved by the ethics committee at Lund University (permit no.2011263). Islet preparation for cadaver donors, their purity check and counting procedure have been described previously 56 . Static in vitro insulin secretion assay from 91 islets (nondiabetic individuals) was performed as described previously 56, 57 . Briefly, six batches of 12 islets per donor were incubated for 1 h at 37 °C in KRB buffer in the presence of 1 mM or 16.7 mM glucose. Independently, KCl-based insulin secretion assay was performed by incubating in 70 mM KCl together with 1 mM or 16.7 mM glucose in a subset of islets in different batches. Insulin concentrations in the extracts were measured using a radioimmunoassay kit (Euro-Diagnostica). The association of p.Trp325Arg genotype with expression of SLC30A8 and other candidate genes was performed using RNA sequencing from islets of 139 nondiabetic individuals, as described previously 54, 55 (see the Supplementary Note).
Statistics. Detailed information regarding statistical tests (two-tailed; Mann-Whitney U-test or one-sample t-test, genetic association; mixed model or linear regression or quantitative transmission disequilibrium tests) used for each substudy have been provided in their respective method section or with the figure legends. Sample size details can be found in the figure legends and Source Data. For electrophysiology, n are representative of the number of siRNA-transfected cells measured from several passages of the same EndoC-βH1 cell batch. For hormone secretion data, n are representative of independent biological replicates from independent passages of cells.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Next-generation sequencing data have been deposited in the SRA database (PRJNA563975) and the processed counts data can be found in the Supplementary Dataset 1. The individual processed data from cell lines (Figs. 4 and 5), mice studies ( Fig. 6 ) and human islet work ( Fig. 7) A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Authentication
Authentication details available at the site (http://www.univercell-biosolutions.com/human-heart-cells-and-stem-cellsproduction/our-technology/endoc-βh1-a-functional-immortalized-human-beta-cell). In Oxford (EndoC-βH1): The EndoC-βH1 has not been authenticated by formal STR profiling, but the cell line is routinely subjected to rigorous testing in a number of different ways, all of which have confirmed the identity as a bona fide human beta cell line. Relevant tests include microarray-based genotyping, RNA-seq, ATAC-seq, and extensive cellular phenotyping, including insulin secretion and content (see Thomsen 
Mycoplasma contamination
Cell-lines tested negative for the Mycoplasma on our regular test.
Commonly misidentified lines
(See ICLAC register) N/A Palaeontology Specimen provenance Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).
Specimen deposition
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Dating methods
If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals light/dark cycle, 60-70% humidity) and fed ad libitum with either chow (Purina Laboratory 23 Rodent Diet 5001, LabDiet) or high-fat diet (Research Diets, D12492; 60% fat by calories) starting at age 20 weeks.
Wild animals
No wild animal were used in this study
Field-collected samples
No field-collected samples were used in this study
Human research participants
Policy information about studies involving human research participants
Population characteristics
Population characteristics of human population have been provided in Supplementary Table 1-3, Supplementary Table 7 and in Method section (Intravenous glucose tolerance test study group).
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ChIP-seq

Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links
May remain private before publication.
For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.
Files in database submission
Provide a list of all files available in the database submission.
Genome browser session (e.g. UCSC)
Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.
Methodology Replicates
Describe the experimental replicates, specifying number, type and replicate agreement.
Sequencing depth
Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired-or single-end.
Antibodies
Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.
Peak calling parameters
Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
Data quality
Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
Software
Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation iPSC cells were collected as a single cell suspension using Accutase. Fixation, permeabilization and staining was performed as outlined by the BD Human Pluripotent Stem Cell Transcription Factor Analysis Kit (Catalog: 560589).
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